PL2667715T3 - Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego - Google Patents
Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowegoInfo
- Publication number
- PL2667715T3 PL2667715T3 PL12739509T PL12739509T PL2667715T3 PL 2667715 T3 PL2667715 T3 PL 2667715T3 PL 12739509 T PL12739509 T PL 12739509T PL 12739509 T PL12739509 T PL 12739509T PL 2667715 T3 PL2667715 T3 PL 2667715T3
- Authority
- PL
- Poland
- Prior art keywords
- methylprolyl
- glycyl
- treatment
- glutamic acid
- autism spectrum
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title 1
- BUSXWGRAOZQTEY-SDBXPKJASA-N trofinetide Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@]1(C)CCCN1C(=O)CN BUSXWGRAOZQTEY-SDBXPKJASA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161462141P | 2011-01-27 | 2011-01-27 | |
| US201161492248P | 2011-06-01 | 2011-06-01 | |
| PCT/US2012/000047 WO2012102832A1 (en) | 2011-01-27 | 2012-01-27 | Treatment of autism spectrum disorderes using glycyl-l-2-methylprolyl-l-glutamic acid |
| EP12739509.3A EP2667715B1 (en) | 2011-01-27 | 2012-01-27 | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2667715T3 true PL2667715T3 (pl) | 2018-02-28 |
Family
ID=46581110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12739509T PL2667715T3 (pl) | 2011-01-27 | 2012-01-27 | Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9708366B2 (pl) |
| EP (1) | EP2667715B1 (pl) |
| JP (3) | JP6348283B2 (pl) |
| AU (1) | AU2012209466C1 (pl) |
| BR (1) | BR112013018898B1 (pl) |
| CA (1) | CA2823218C (pl) |
| CO (1) | CO6791613A2 (pl) |
| CY (1) | CY1119455T1 (pl) |
| DK (1) | DK2667715T3 (pl) |
| ES (1) | ES2641880T3 (pl) |
| HR (1) | HRP20171478T1 (pl) |
| HU (1) | HUE036637T2 (pl) |
| IL (1) | IL227669B (pl) |
| LT (1) | LT2667715T (pl) |
| PL (1) | PL2667715T3 (pl) |
| PT (1) | PT2667715T (pl) |
| RS (1) | RS56461B1 (pl) |
| SI (1) | SI2667715T1 (pl) |
| SM (1) | SMT201700485T1 (pl) |
| WO (1) | WO2012102832A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201700485T1 (it) | 2011-01-27 | 2017-11-15 | Neuren Pharmaceuticals Ltd | Trattamento di disturbi dello spettro autistico usando acido glicil-l-2-metilprolil-l-glutammico |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| JP2016506380A (ja) * | 2012-11-28 | 2016-03-03 | ニューレン ファーマシューティカルズ リミテッド | グリシル−l−2−メチルプロリル−l−グルタミン酸を使用する自閉症スペクトラム障害の処置 |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| SG11201602161XA (en) | 2013-09-23 | 2016-04-28 | Wolff August Gmbh & Co Kg Arzneimittel Dr | Anti-inflammatory tripeptides |
| ES3014042T3 (en) * | 2014-06-06 | 2025-04-16 | Meizon Innovation 2 Pty Ltd | Trans-10-hydroxy-2-decenoic acid for use in the treatment of autism spectrum disorder |
| RU2608444C1 (ru) * | 2015-10-02 | 2017-01-18 | Закрытое Акционерное Общество "Алмаз Фарм" | Средство для лечения и профилактики расстройств аутистического спектра |
| US20180296647A1 (en) | 2015-10-14 | 2018-10-18 | Kurume University | Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| JP2019514961A (ja) * | 2016-05-04 | 2019-06-06 | ニューロトロープ バイオサイエンス インコーポレイテッド | レット症候群を処置するための方法及び組成物 |
| JP7182554B2 (ja) | 2016-11-14 | 2022-12-02 | コグノア,インク. | 発達に係る疾病を評価し、およびカバー率と信頼度に対する制御を提供する方法および装置 |
| PL3570940T3 (pl) * | 2017-01-20 | 2024-06-17 | Prilenia Neurotherapeutics Ltd. | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
| EP3580700A4 (en) | 2017-02-09 | 2020-11-18 | Cognoa, Inc. | PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE |
| CA3128037A1 (en) * | 2019-02-01 | 2020-08-06 | Revivo Therapeutics | Nomethiazoles as a treatment for rett syndrome |
| KR102643554B1 (ko) * | 2019-03-22 | 2024-03-04 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| KR20220059479A (ko) * | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| WO2021086892A1 (en) * | 2019-10-28 | 2021-05-06 | Acadia Pharmaceuticals Inc. | Methods and compositions for treatment of rett syndrome |
| EP4138880A4 (en) * | 2020-04-24 | 2024-08-07 | New York University | Use of igf-2 for treatment of epileptic seizures |
| IT202100004964A1 (it) * | 2021-03-03 | 2022-09-03 | Univ Degli Studi Di Bari Aldo Moro | Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico. |
| IL310045A (en) * | 2021-07-12 | 2024-03-01 | Acadia Pharm Inc | Crystalline forms of trofinetide |
| CN114128672B (zh) * | 2021-11-21 | 2023-04-07 | 河南省儿童医院郑州儿童医院 | 一种孤独症大鼠模型的构建方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0350973B1 (de) | 1983-09-26 | 1997-11-05 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| DK15888D0 (da) | 1988-01-14 | 1988-01-14 | Carlsberg Biotechnology Ltd | Enzymatisk fremgangsmaade til fremstilling af immunmodulerende pentapeptider samt mellemprodukter til brug ved fremgangsmaaden |
| SE8803847A0 (sv) | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| WO1995017204A1 (en) | 1993-12-23 | 1995-06-29 | Auckland Uniservices Limited | Composition and methods to improve neural outcome |
| EP0756494A1 (en) | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| WO1998014202A1 (en) | 1996-10-04 | 1998-04-09 | Auckland Uniservices Limited | Regulation of neural enzymes |
| EP1087782A4 (en) | 1998-06-15 | 2001-09-12 | Neuronz Ltd | REGULATION OF TYROSINE HYDROXYLASE |
| BR0015025A (pt) * | 1999-10-26 | 2002-06-18 | Janssen Pharmaceutica Nv | Solução oral contendo galantamina e um agente adoçante |
| AU2001289160A1 (en) | 2000-08-24 | 2002-03-04 | Neuronz Ltd. | Gpe analogs |
| US8637567B2 (en) | 2001-05-24 | 2014-01-28 | Neuren Pharmaceuticals Ltd. | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid |
| US20070004641A1 (en) | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
| ES2325983T3 (es) | 2001-05-24 | 2009-09-28 | Neuren Pharmaceuticals Limited | Analogos y peptidomimeticos de gpe. |
| US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
| US7863304B2 (en) | 2001-05-24 | 2011-01-04 | Neuren Pharmaceuticals Limited | Analogs of glycyl-prolyl-glutamate |
| US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
| US7714070B2 (en) | 2002-08-27 | 2010-05-11 | Sunoco Chemicals, Inc. | In-reactor produced polypropylene blends |
| AU2005286943A1 (en) * | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (NAMENDA) to treat autism, compulsivity, and impulsivity |
| EP1888618A4 (en) * | 2005-05-23 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Analogs of glycyl-prolyl-glutamate |
| JP5220724B2 (ja) * | 2006-03-14 | 2013-06-26 | ニューレン ファーマシューティカルズ リミテッド | グリシル−2−メチルプロリルグルタミン酸塩の経口製剤 |
| GB0707127D0 (en) * | 2007-04-13 | 2007-05-23 | Zysis Ltd | Pharmaceutical compositions |
| CA2689549A1 (en) | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| US7863309B2 (en) | 2008-07-24 | 2011-01-04 | Theravance, Inc. | Dual-acting antihypertensive agents |
| AU2010204995A1 (en) | 2009-01-16 | 2011-08-18 | Massachusetts Institute Of Technology | Diagnosis and treatment of autism spectrum disorders |
| WO2011146109A2 (en) | 2010-05-17 | 2011-11-24 | Mount Sinai School Of Medicine | Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression |
| SMT201700485T1 (it) | 2011-01-27 | 2017-11-15 | Neuren Pharmaceuticals Ltd | Trattamento di disturbi dello spettro autistico usando acido glicil-l-2-metilprolil-l-glutammico |
-
2012
- 2012-01-27 SM SM20170485T patent/SMT201700485T1/it unknown
- 2012-01-27 ES ES12739509.3T patent/ES2641880T3/es active Active
- 2012-01-27 HU HUE12739509A patent/HUE036637T2/hu unknown
- 2012-01-27 US US13/699,087 patent/US9708366B2/en active Active
- 2012-01-27 HR HRP20171478TT patent/HRP20171478T1/hr unknown
- 2012-01-27 PT PT127395093T patent/PT2667715T/pt unknown
- 2012-01-27 EP EP12739509.3A patent/EP2667715B1/en active Active
- 2012-01-27 SI SI201231075T patent/SI2667715T1/sl unknown
- 2012-01-27 RS RS20171001A patent/RS56461B1/sr unknown
- 2012-01-27 WO PCT/US2012/000047 patent/WO2012102832A1/en active Application Filing
- 2012-01-27 JP JP2013551979A patent/JP6348283B2/ja active Active
- 2012-01-27 CA CA2823218A patent/CA2823218C/en active Active
- 2012-01-27 LT LTEP12739509.3T patent/LT2667715T/lt unknown
- 2012-01-27 DK DK12739509.3T patent/DK2667715T3/en active
- 2012-01-27 BR BR112013018898-7A patent/BR112013018898B1/pt active IP Right Grant
- 2012-01-27 AU AU2012209466A patent/AU2012209466C1/en active Active
- 2012-01-27 PL PL12739509T patent/PL2667715T3/pl unknown
-
2013
- 2013-07-25 IL IL227669A patent/IL227669B/en active IP Right Grant
- 2013-08-23 CO CO13200227A patent/CO6791613A2/es not_active Application Discontinuation
-
2015
- 2015-01-26 US US14/605,420 patent/US9212204B2/en active Active
-
2016
- 2016-09-09 JP JP2016176567A patent/JP6342459B2/ja active Active
-
2017
- 2017-10-12 CY CY20171101074T patent/CY1119455T1/el unknown
-
2018
- 2018-05-16 JP JP2018094320A patent/JP6640275B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2667715T (lt) | Autizmo spektro susirgimų gydymas, naudojant glicil-l-2-metilprolil-l-glutamo rūgštį | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| EP2717855A4 (en) | PROCESSING METHODS | |
| GB201110095D0 (en) | Method of treatment | |
| EP2773754A4 (en) | Methods of Treatment | |
| ZA201205829B (en) | Treatment of respiratory disorders | |
| IL233111A0 (en) | Preparations for the treatment of inflammation | |
| GB201202773D0 (en) | Compositions for treatment of skin disorders | |
| IL225896A0 (en) | Treatment of mecp-2 related disorders | |
| EP2709665A4 (en) | TREATMENT OF PSORIASIS | |
| PL395112A1 (pl) | Zastosowanie klenbuterolu do leczenia autyzmu | |
| IL239273A0 (en) | A method of treating diseases | |
| ZA201308194B (en) | Treatment of mastitis | |
| GB201107467D0 (en) | Novel treatment of pain | |
| EP2791324A4 (en) | PROCESSING METHOD | |
| GB201218263D0 (en) | Treatment of autism | |
| GB201101773D0 (en) | Treatment of inflammatory disorders | |
| GB201101183D0 (en) | Treatment of neurodegenerative disorders | |
| GB201100651D0 (en) | Treatment of inflammation | |
| GB201119458D0 (en) | Compositions for treatment of sleep disorders | |
| GB201118065D0 (en) | Treatment of movement disorders | |
| GB201110602D0 (en) | Methods of treatment | |
| GB201109737D0 (en) | Methods of treatment | |
| GB201121044D0 (en) | Treatment of solutions | |
| IL228973A0 (en) | Oxymetazoline for the treatment of anorectal disorders |